Comparing the current results to its competitors, Rhythm Pharmaceuticals Inc reported Revenue increase in the 2 quarter 2026 by 46.91 % year on year. The sales growth was above Rhythm Pharmaceuticals Inc 's competitors' average revenue growth of 5.15 %, achieved in the same quarter.
Due to outstanding performance in Overall company, revenue grew by 46.91 % Rhythm Pharmaceuticals Inc improved its market share, to approximately 0.61 %.
November 4, 2024
At ObesityWeek 2024, Rhythm Pharmaceuticals took center stage by presenting compelling new data on the efficacy of setmelanotide, a breakthrough therapy aimed at battling acquired hypothalamic obesity, a complex and challenging condition leading to severe weight abnormalities. The presentations highlighted promising results, driving interest in the potential of setmelanotide to become a significant therapeutic option for patients grappling with this debilitating form of obesity.Acquired hypothalamic obesity often arises following damage to the hypothalamus, usually due to surgery, trauma, or tumors. It results in significant metabolic and hormonal disruptions that cause uncontrollable weight gain and related...
February 22, 2024
Rhythm Pharmaceuticals Expands Clinical Development Plan for Setmelanotide in JapanRhythm Pharmaceuticals has recently announced the expansion of its clinical development plan for Setmelanotide in Japan, specifically targeting patients suffering from hypothalamic obesity. This development comes as a response to the significant unmet need in Japan, with an estimated 5,000 to 8,000 patients living with this condition.The company plans to add a supplemental cohort of 12 Japanese patients to its ongoing global Phase 3 trial for hypothalamic obesity. Dosing is expected to commence in the third quarter of 2024. This expansion aims to evaluate the safety and efficacy of Setmelanotide in a Japanese population, furth...
January 4, 2024
In an exciting development in the field of metabolic disorders, Rhythm Pharmaceuticals has recently entered into an agreement with LG Chem Life Sciences to acquire global rights to the oral MC4R agonist LB54640. This novel therapy has shown a targeted effect on the MC4 receptor without the side effect of hyperpigmentation. Rhythm Pharmaceuticals is set to advance LB54640 in two Phase 2 clinical trials, paving the way for a potential breakthrough in the treatment of metabolic disorders.1. LB54640: A Promising Oral MC4R AgonistLB54640, developed by LG Chem Life Sciences, represents a significant advancement in the quest for effective therapies targeting metabolic disorders such as obesity. It is an oral MC4R (...
Publicly Traded Peers of Rhythm Pharmaceuticals Inc
Praxis Precision Medicines Inc Share Performance
+26.13%
This Quarter
Praxis Precision Medicines Inc
Profile
Praxis Precision Medicines Inc's business model revolves around developing precision medicines for the treatment of various central nervous system (CNS) disorders.
Ideaya Biosciences Inc operates on a precision medicine approach that combines genomics and synthetic lethality to develop targeted cancer therapies. The company focuses on identifying synthetic lethal interactions in cancer and leveraging these insights to discover and develop drugs that selectively target cancer cells. They collaborate with academic institutions and industry partners to advance their therapeutic pipeline and bring innovative treatments to patients in need.
Merus N V is a biotechnology company that operates using a differentiated and competitive business model. Their approach involves strategically targeting and developing bispecific antibodies to treat various types of cancer, leveraging their proprietary technologies and expertise in the field. By focusing on innovative research, efficient drug discovery, and partnerships, they aim to improve patient outcomes and drive growth in the oncology market.
Xoma Corporation operates under a business model focused on the development and commercialization of novel therapeutics. The company primarily concentrates on creating antibody-based therapies to address unmet medical needs. Xoma also engages in collaborations and partnerships with other pharmaceutical companies to advance their product pipeline and expand their reach in the market.
Urogen Pharma Ltd is a pharmaceutical company that specializes in developing and commercializing innovative therapies for urological and oncological conditions. Their business model revolves around conducting extensive research and development to create novel therapies, obtaining necessary regulatory approvals, and strategically partnering with healthcare providers and other stakeholders to market and distribute their products globally. By focusing on addressing unmet medical needs in the urology field, Urogen Pharma aims to improve patient outcomes and establish a strong presence in the market.
Sources:
Rhythm Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Rhythm Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
